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Abstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of 
conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medica-
tions for the treatment of psychosis in both acute and chronic conditions. Those conditions include 
schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased 
risk of adverse events from antipsychotic medications because of age-related pharmacodynamic 
and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized 
to the patient’s previous history of antipsychotic use, current medical conditions, potential drug 
interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects 
should be closely monitored in this population. This paper provides a review of aripiprazole, 
a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in 
the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depres-
sion. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as 
dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. 
We will also detail patient focused perspectives including quality of life, patient satisfaction 
and adherence.
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Introduction
Antipsychotic medications are commonly prescribed for older adults for the acute 
management of psychosis in brief psychotic disorders or in psychosis due to a general 
medical condition or from substance use. Chronic antipsychotic therapy is commonly 
used in patients with psychosis, schizophrenia, dementia related psychosis, bipolar 
disorder, and psychosis related to Parkinson’s disease.
Elderly patients are at increased risk of adverse drug events because of age-related 
pharmacodynamic and pharmacokinetic changes. Additionally, as older adults are often 
prescribed multiple medications, they are at increased risk for drug–drug interactions. 
Common side effects in the elderly from antipsychotics include orthostatic hypoten-
sion, sedation, anticholingergic side effects, extrapyramidal symptoms (tremor and 
rigidity), and tardive dyskinesia (lip smacking).
This paper provides a review of aripiprazole, a newer atypical antipsychotic agent. 
We will review the indications and adverse drug reactions of this drug in the elderly. 
Specifically, we will review pharmacokinetics and pharmacodynamics of aripiprazole 
as well as dosing, diagnostic indications, efficacy studies, and tolerability. We will 
also detail patient focused perspectives including quality of life, patient satisfaction 
and adherence.Neuropsychiatric Disease and Treatment 2010:6 48
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Psychosis in the elderly
Delusions, hallucinations and other psychotic symptoms 
can accompany a number of conditions in late life. A recent 
Swedish investigation found that the prevalence of any 
psychotic symptom in a population sample of 85-year-old 
individuals without dementia was 10.1%.1 Some conditions 
that cause psychotic symptoms, such as delirium and 
substance-induced psychosis are acute and tend to resolve 
when the underlying condition is treated.2 Psychotic 
symptoms in elderly individuals may also arise secondarily 
to Alzheimer’s disease (AD) or other dementias. AD is the 
most common form of dementia in the elderly population, 
accounting for 65% to 70% of dementia cases. Approximately 
35% to 50% of AD patients manifest psychotic symptoms.3 
Psychosis associated with AD often presents with paranoid 
and nonbizarre delusions.4 Misidentification of care givers 
is common in patients with AD, while schneiderian first rank 
symptoms are rare.5
Schizophrenia in the elderly
Schizophrenia, a chronic, mental illness affects about ∼1% of 
the US population and is characterized by both positive and 
negative symptoms, cognitive dysfunction and a decline in 
psychosocial functioning.6 The etiology of schizophrenia is 
unknown, but it is believed that monoamine neurotransmitter 
systems, particularly dopaminergic neurons, are involved.7 
Most individuals with schizophrenia develop the disease 
in the second or third decade of life. Many patients with 
schizophrenia now live into older adulthood. Thus, about 80% 
of older adults with schizophrenia have had an early onset 
of the disease and have a chronic course spanning several 
decades.8 There is another smaller subset of patients who 
develop psychotic symptoms after age 60 and are diagnosed 
with very late onset schizophrenia-like psychosis.9 Factors 
distinguishing patients with very late onset schizophrenia 
from early onset schizophrenia patients include a lower 
genetic load, less evidence of a thought disorder, and evidence 
of a neurodegenerative component.10 The prevalence of 
schizophrenia among individuals aged 45 to 64 is approxi-
mately 0.6% and prevalence estimates for elderly individuals 
range from 0.1% to 0.5%.11,12
Longitudinal follow-up of patients with schizophrenia 
indicates a wide range of outcomes. About 20% of patients 
experience remission of all symptoms.13 Another 20% 
experience worsening of their symptoms and the remain-
ing 60% remain largely unchanged.14 Factors associated 
with poorer prognosis include chronicity, insidious 
onset, premorbid functional deficits, and prominent 
negative symptoms.15 In one large sample of chronically 
institutionalized patients with schizophrenia, older age 
was associated with lower levels of positive symptoms and 
higher levels of negative symptoms.16 Cognitive perfor-
mance tends to be stable, although it is worse in patients 
with schizophrenia than in healthy adults.17 The degree 
of functional impairment varies among older adults with 
schizophrenia. However, one study showed that 30% of 
a group of older schizophrenic patients was employed at 
least part-time since the onset of psychosis and that 73% 
of them were living independently.18
Psychosis in Alzheimer’s dementia 
in the elderly
Alzheimer’s disease (AD) affects 5% to 15% of the population 
over age 65 and about 20% of individuals over age 80.19 
There is a high prevalence of psychotic symptoms and 
behavioral disturbance in AD. A review of studies showed 
a median prevalence rate of psychosis in AD of 41.1% 
(range, 12.2% to 74.1%).20,21 Psychotic symptoms have 
been linked to increased cognitive and functional decline 
and increased risk of institutionalization in patients 
with AD.22
Antipsychotic medications are disproportionately used 
among elderly persons and are prescribed for more than a 
quarter of Medicare beneficiaries in nursing homes.23 Such 
medications are often used for dementia, delirium, psychosis, 
agitation, and affective disorders.24 Even though there is no 
psychotropic medication that is approved by the US Food and 
Drug Administration (FDA) for the treatment of psychosis in 
AD, a number of consensus statements prior to 2004 recom-
mend the use of atypical antipsychotic agents as a first line 
pharmacologic approach to treatment.25
Analyses of safety data from several studies have raised 
concerns about an increased risk of cerebrovascular adverse 
events such as stroke in the use of certain atypical anti-
psychotics compared with placebo in elderly patients with 
dementia.26,27 This has led the FDA to issue warnings on the 
use of atypical antipsychotics in the treatment of behavioral 
symptoms in elderly patients with dementia.19 In a Public 
Health Advisory issued in April 2005, the FDA warned that 
the use of atypical antipsychotic medications nearly doubled 
the risk of death, as compared with the risk with placebo, 
in 17 short-term, randomized, controlled trials involving 
elderly persons with dementia.28 The FDA has issued a 
separate warning regarding the increased mortality risk in 
elderly patients with dementia who are treated with atypical 
antipsychotics including aripiprazole.29Neuropsychiatric Disease and Treatment 2010:6 49
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Bipolar disorder in the elderly
Bipolar disorder in older adult populations has gained 
increasing attention due to the growing proportion of elderly 
in the United States and worldwide.30 One study reported the 
prevalence of bipolar disorder at 0.5% among individuals 
age 65 and older as bipolar illness persists into later life.31 
A continuing unmet need is the identification of agents that 
are generally well tolerated and effective in later-life bipolar 
disorder. Medications that are first-line treatments in younger 
patients, such as lithium, may be poorly tolerated in older 
patients due to side effects and renal dysfunction. Additional 
strategies for bipolar disorder in late-life are needed. There 
are few evidence-based studies on which to base treatment 
decisions in geriatric patients with bipolar disorder.32
Psychosis in Parkinson’s disease
Psychosis affects at least 5% to 8% of medication-treated 
patients with idiopathic Parkinson’s disease (PD).33 Treatment 
options include reducing medications used for the treatment of 
PD-related motor symptoms or introducing an atypical anti-
psychotic drug. Only clozapine has been demonstrated to be 
efficacious and tolerated in double-blind controlled trials.34
Major depressive disorder in the elderly
Major depressive disorder (MDD) is common in older adults, 
with estimates of prevalence of 6% to 10% in primary care 
population.35 Approximately 50% of older patient with 
MDD do not respond completely to initial treatment with 
antidepressant pharmacotherapy.36 Recently, the use of 
atypical antipsychotic agents has been studied as adjunctive 
or augmentation pharmacotherapy for incomplete response 
in young to middle-aged adults with major depression.37 
The addition of aripiprazole to standard antidepressant 
pharamacotherapy has been examined in young and mid-life 
patients with MDD.38
Pharmacology and 
pharmacokinetics/dynamics  
of aripiprazole
Aripiprazole is a second-generation (atypical) antipsychotic 
that is approved for schizophrenia, manic or mixed episodes 
associated with biploar I disorder, and as an adjunctive treat-
ment of major depressive disorder. It exhibits high affinity for 
D2, D3, 2-HT1a and 5-HT2a receptors, moderate affinity for 
D4, 5-HT2c, 5-HT7, alpha 1 adrenergic and H1 receptors, 
and no affinity for muscarinic receptors. It has moderate 
affinity for the serotonin reuptake transporter.39 The proposed 
mechanism of action for its efficacy is a combination of 
partial agonistic activity at D2 and 5-HT1A receptors and 
antagonistic activity at 5-HT2A receptors.40 It is available in 
several dosage forms: intramuscular injection solution, oral 
solution, tablets, and orally disintegrating tablets.41
Table 1 compares the pharmacokinetic parameters of 
second-generation antipsychotics. Aripripazole has an active 
Table 1 Pharmacokinetic parameters of selected antipsychotics101
Drug Bioavailability (%) Half-life (h) Major metabolic 
pathway
Active 
metabolites
Dosage 
forms
Aripiprazole 87 48–68 
Dehydroaripiprazole: 
75–46
CYP3A4,  
CYP2D6
Y T, O, L
Clozapine 12–81 11–105 CYP1A2,  
CYP3A4, 
CYP2C19
Y T, O
Olanzapine 80 20–70 CYP1A2,  
CYP3A4,  
FMO3
Y T, i, O
Paliperidone er 28 23 renal unchanged 
(59%)  
Multiple pathway
N er
Quetiapine 5–13 7 CYP3A4 Y T
risperidone 68 3–24 CYP2D6 Y T, O, L
risperidone Consta® 3–6 days CYP2D6 Y LAi
Ziprasidone 59 4–10 Aldehyde oxidase, 
CYP3A4
N C, i
Abbreviations: C, capsules; er, extended release; i, injection; L, liquid solution, elixir or suspension; LAi, long-acting injectable; O, orally disintegrating tablets;   T, tablet.Neuropsychiatric Disease and Treatment 2010:6 50
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metabolite (dehydroaripiprazole) that has affinities for D2 
receptors and an elimination half-life of 94 hours. The drug 
reaches the peak plasma concentration (Tmax) between 3 to 
5 hours, and achieves a steady-state concentration within 
14 days. It can be taken with or without food, but high-fat 
meal delays Tmax by 3 hours. Aripiprazole has a high volume 
of distribution (4.9 L/kg) and is highly bound to albumin 
(99%). Due to its long half-life, high volume of distribution 
and high protein binding, the elderly patients may experience 
drug accumulation and drug interactions. It is particularly 
true in patients who have low albumin levels, which may end 
up with higher free aripriprazole drug concentration. Exces-
sive drug effect in this population may justify dose reduction 
or extended dosing interval. In addition, aripriprazole is 
metabolized primarily by dehydrogenation and hydroxyl-
ation (CYP3A4 and CYP2D6), as well as N-dealkylation 
(CYP3A4). Due to CYP450 enzyme polymorphism, its 
elimination half-life may be prolonged to up to 150 hours 
in poor metabolizers which represents approximately 8% of 
Caucasians. Approximately 25% of the drug is excreted in 
the urine (1% as unchanged drug) and 55% in the feces 
(18% as unchanged drug). Intramuscular doses have a bio-
availability of 100%, and a Tmax of 1 to 3 hours. Compared to 
oral doses, intramuscular doses achieve a 19% higher peak 
plasma concentration, as well as a 90% higher drug exposure 
within 2 hours of dosing.41,42
Aripiprazole interacts with drugs that are inducers or 
inhibitors of CYP3A4 and CYP2D6 enzymes.43 The dose 
should be doubled when coadministered with CYP3A4 
inducers, such as carbamazepine. The dose should be reduced 
to half of the usual dose if coadministered with CYP3A4 
inhibitors (ketoconazole) or CYP 2D6 inhibitors (fluoxetine, 
paroxetine).44 Appropriate measures should be done when 
the interacting drugs are discontinued. No dosage adjustment 
is required in patients with renal or hepatic impairment.45 
Intramuscular injections should be administered slowly into 
deep muscle mass. Oral doses may be administered with or 
without food. Tablet and oral solution may be interchanged 
on a mg-per-mg basis, up to 25 mg. Doses using 30 mg tablets 
should be exchanged for 25 mg oral solution.41 Orally disin-
tegrating tablets are bioequivalent to the immediate release 
tablets, and should be placed in mouth immediately upon 
removal from foil blister. They dissolve rapidly in saliva and 
may be swallowed without liquid.
Table 2 shows the relative side effect incidence of selected 
antipsychotics in all age groups. However, use of antipsychot-
ics in the elderly is linked with many unique concerns. Firstly, 
anticholinergic effects can be detrimental to those who may 
already have urinary symptoms, cognitive impairment, dry 
mouth, blurred vision and cardiac abnormalities. Secondly, 
orthostatic hypotension and sedation may contribute to falls 
in patients who have trouble with balance and gait. Thirdly, 
extrapyramidal symptoms can be associated with long term 
antipsychotic therapy. Patients with the comorbidity of PD 
are especially at risk for tremor and muscle rigidity. Arip-
riprazole has lower incidence of these troublesome adverse 
effects when compared to other available antipsychotics. 
A retrospective study evaluated the use of aripriprazole for 
schizophrenia/schizoaffective disorder, bipolar disorder 
and major depressive disorder in elderly patients. The study 
suggested that agitation/activation is the most commonly 
reported side effect.46
Aripiprazole efficacy studies
Schizophrenia
The recommended dosage for schizophrenia is 10 to 15 mg 
once daily, titrate no more frequently than every 2 weeks, 
to maximum of 30 mg daily. Aripiprazole demonstrated 
its efficacy in four short-term placebo controlled trials that 
enrolled acutely relapsed inpatients with schizophrenia. Three 
of these studies also included an active control group treated 
with either risperidone (one trial) or haloperidol (two trials). 
Table 2 relative side effect incidence of selected antipsychotics in the general population101
Drug Sedation EPS Anticholinergic Orthostasis Weight gain Hyperprolactinemia
Aripiprazole + + + + + +
Clozapine ++++ + ++++ ++++ ++++ +
Haloperidol + ++++ + + + ++++
Olanzapine ++ ++ ++ ++ ++++ +
Quetiapine ++ + + ++ ++ +
risperidone + ++ + ++ ++ ++++
Ziprasidone ++ ++ + + + +
Notes: + = low degree of symptoms, ++ = medium degree of symptoms, ++++ = high degree of symptoms.Neuropsychiatric Disease and Treatment 2010:6 51
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The primary measures were the Positive and Negative 
Syndrome Scale (PANSS)47 and the Clinical Global Impression 
(CGI)48 assessment. PANSS measures positive symptoms 
(delusions, conceptual disorganization, hallucinatory 
behavior, excitement, grandiosity, suspiciousness/persecution, 
and hostility) and negative symptoms (blunted affect, emo-
tional withdrawal, poor rapport, passive apathetic withdrawal, 
difficulty in abstract thinking, lack of spontaneity/flow of 
conversation, stereotyped thinking). The CGI assessment 
reflects the impression of a skilled observer about the overall 
clinical state of the patient.48
Overall, aripiprazole (10 to 30 mg daily) is more effica-
cious than placebo in all measure outcomes after 4 to 6 week 
of therapy.49–51 In a 6-week trial (n = 367), aripriprazole 
10 mg daily is superior to placebo in PANSS total score, 
but the lower dose groups did not demonstrate superiority 
to placebo.52 In another 4-week placebo controlled trial 
(n = 103) comparing the dose range of 5 mg daily to 30 mg 
daily. Aripiprazole demonstrated efficacy only in a responder 
analysis based on the CGI-severity score. Overall, higher 
dose of aripiprazole offered no advantage over the lowest 
doses. A longer-term trial (n = 310) that enrolled patients 
who were symptomatically stable on other antipsychotic 
medications for at least 3 months. These patients were 
discontinued from their antipsychotic medications and 
randomized to aripiprazole 15 mg daily or placebo for up 
to 26 weeks of observation for relapse. Patients receiving 
aripiprazole experienced a significantly longer time to 
relapse, defined as CGI Improvement score of 5 (minimally 
worse), scores 5 (moderately severe) on the hostility or 
uncooperativeness items of the PANSS, or 20% increase in 
the PANSS total score.53 These clinical trials did not include 
sufficient numbers of subjects aged 65 and over to determine 
whether they respond differently from younger patients.
Clinical trials of aripiprazole included few elderly 
patients and more data are needed on the effects of aripip-
razole in this population, especially those with comorbid 
medical illnesses.54 In one study, aripiprazole was used 
to treat 10 elderly hospitalized patients between 62 and 
85 years of age who manifested signs of psychosis related 
to schizophrenia or schizoaffective disorder. All patients 
had been treated previously with atypical and classic anti-
psychotics. Response was assessed by clinical observation 
of patients’ behavior and Clinical Global Impression Scale 
assigned retrospectively. Seven patients responded to treat-
ment, two did not respond, and one had a partial response. 
The mean Clinical Global Impression Scale scores improved 
from 6 (severely ill) at baseline to 2.3 (much improved) at 
discharge. Treatment was discontinued in the two patients 
who did not respond. Of the 7 patients who responded, 
4 presented with positive symptoms and showed significant 
improvement while 3 presented with positive and negative 
symptoms and both symptoms improved significantly. Four 
patients had preexisting EPS and these symptoms decreased 
in three patients. In addition, two patients were able to dis-
continue antiparkinson medications. The reduction of both 
positive and negative symptoms of schizophrenia and the 
lack of significant EPS, tardive dyskinesia, sedation, weight 
gain, anticholinergic effects, and QTc prolongation gives 
preliminary indication that aripiprazole may be a safe and 
effective medication for elderly patients with schizophrenia 
or schizoaffective disorder.55
Psychosis in Alzheimer’s dementia  
in the elderly
There have been three 10-week, placebo-controlled studies 
that have evaluated the efficacy and tolerability of aripip-
razole for the treatment of psychosis related to AD.19 In 
the De Deyn et al study, there were 208 outpatients who 
were given flexible dosing of aripiprazole (doses of 2 to 
15 mg/day). There was no statistical difference between 
aripiprazole and placebo in the primary outcome measure of 
the caregiver-assessment NPI psychosis subscale. However, 
the aripiprazole-treated patients showed significantly greater 
improvement on the Brief Psychiatric Rating Scale (BPRS) 
Psychosis and BPRS Core subscale scores at end point when 
compared to placebo. There was no statistical significant 
difference in the BPRS total score.56
In the Streim et al study, there were 256 inpatients with 
AD-related psychosis who were given flexible dosing of 
aripiprazole (doses of 2 to 15 mg/day) with a mean aripip-
razole dose at end point of 8.6 mg/day. There was also no 
statistical difference between aripiprazole and placebo in 
the primary outcome measure of the caregiver-assessment 
NPI psychosis subscale. There were decreases in the Clini-
cal Global Impression-Severity of Illness (CGI-S), but those 
were only clinically significant in week 8. There was also 
statistically significant improvement in the Cohen-Mansfield 
Agitation Inventory (CMAI).57
In the Mintzer et al study, 487 institutionalized nursing home 
patients were randomized to fixed doses of either 2 mg/day, 
5 mg/day, or 10 mg/day. On the 10 mg/d dose, there was a 
statistically significant difference between aripiprazole and 
placebo on the Neuropsychiatric Inventory-Nursing Home 
(NPI-NH) Psychosis subscale score at week 10.58 It is impor-
tant to note that the incidence of EPS-related AEs in these Neuropsychiatric Disease and Treatment 2010:6 52
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studies was low across all treatment groups.19 There was no 
significant difference between placebo and aripiprazole in 
all the three studies for weight change.19
Psychosis in Parkinson’s disease
One study evaluated the effect of aripiprazole on psychosis 
in PD in an open-label pilot study. Fourteen patients meet-
ing entry criteria were started on aripiprazole 1 mg/day and 
titrated up to a maximum dose of 5 mg as needed. Subjects 
were evaluated on the Unified Parkinson’s Disease Rating 
Scale (UPDRS) part III for motor function, the Neuropsychi-
atric Inventory (NPI), and the Brief Psychiatric Rating Scale 
(BPRS) for psychiatric response. Statistically significant 
improvement in mean BPRS and positive BPRS subscales 
occurred with open-label aripiprazole, but 8 subjects discon-
tinued the study due to worsened Parkinsonism (3), worsened 
psychosis (2), worsening of both (2), and lack of efficacy (1). 
While some patients had a favorable response, aripiprazole 
was associated with an exacerbation of motor symptoms. 
In that small study on psychosis in PD, aripiprazole did not 
appear promising.59
Bipolar disorder
Aripiprazole is approved by the FDA for the treatment of 
bipolar mania and for the long-term treatment of bipolar 
disorder. To stabilize the acute manic or mixed episodes, 
aripiprazole should be initiated at 15 mg once daily as 
monotherapy or adjunctive to lithium or valproic acid; 
may increase to 30 mg once daily if clinically indicated. 
The effective stabilization dose should be continued for up 
to 6 weeks. Aripiprazole demonstrated its efficacy in four 
3-week, placebo-controlled trials in hospitalized patients 
with bipolar I disorder with manic or mixed episodes. These 
studies included patients with or without psychotic features, 
and 2 studies also included patients with or without a rapid-
cycling course. The primary instrument used for assess-
ing manic symptoms was the Young Mania Rating Scale 
(Y-MRS), an 11-item clinician-rated scale that assesses the 
degree of manic symptomatology (irritability, disruptive/
aggressive behavior, sleep, elevated mood, speech, increased 
activity, sexual interest, language/thought disorder, thought 
content, appearance, and insight). The secondary instrument 
included the Clinical Global Impression – Bipolar (CGI-BP) 
Scale.60–62
As a maintenance therapy, aripiprazole is superior to 
placebo on time to the number of combined affective relapses 
(manic plus depressive), but it is unclear if it delays the time 
to occurrence of depression in these patients. In addition, 
these clinical trials did not include sufficient numbers of 
subjects aged 65 and over to determine whether they respond 
differently from younger patients.
One study looking at the use of aripiprazole in elderly 
patients is an open-label, prospective trial of aripiprazole 
therapy in 20 older adult patients with bipolar disorder.30 
Older adults with bipolar I disorder (confirmed by the Mini-
International Neuropsychiatric Interview) who were currently 
suboptimally responsive to their prescribed medication 
treatments received 12 weeks of open-label aripiprazole added 
on to existing mood stabilizer medication treatment. Aripip-
razole was initiated at 5 mg daily and increased as tolerated. 
Efficacy outcomes included psychopathology measures (the 
Young Mania Rating Scale [YMRS]63 and the Hamilton Rating 
Scale for Depression [HAM-D]),64 extrapyramidal symptoms, 
and a level of functioning measure (the Global Assessment 
Scale [GAS]). Twenty older adults (mean age = 59.6 years, 
range 50 to 83 years) received aripiprazole therapy. Compared 
to baseline, individuals had significant reductions in mean 
depression scores (HAM-D baseline = 13.8, HAM-D end 
point = 6.1, P  0.001), as well as mania scores (YMRS 
baseline = 8.6, YMRS end point = 3.9, P  0.03). There 
were also significant improvements in functional status as 
measured by the GAS (P  0.001). The mean ± SD daily 
dose of aripiprazole was 10.26 ± 4.9 mg/day. Overall, 
aripiprazole was adequately tolerated in this older adult 
population. Aripiprazole therapy may reduce symptoms in 
bipolar older adults, and it appears to be reasonably tolerated. 
However, larger, controlled trials are needed to confirm these 
preliminary findings.30
Agitation associated with schizophrenia 
or bipolar mania
The recommended dosage is 9.75 mg (range 5.25 to 15 mg) 
as a single intramuscular dose, repeat at no more frequently 
than every 2 hours to a maximum of 30 mg daily; transit 
to oral therapy as soon as possible if ongoing therapy is 
indicated. The efficacy of aripiprazole for the treatment of 
agitation was established in 3 short-term (24-hour), placebo-
controlled trials in agitated inpatients with schizophrenia or 
bipolar I disorder (manic or mixed episodes, with or without 
psychotic features). Each trial included an active controlled 
arm of either haloperidol injection (schizophrenia studies) or 
lorazepam injection (bipolar Mania study). The efficacy mea-
sures were the change from baseline in the PANSS Excited 
Component at 2 hours post-injection and the Clinical Global 
Impression of Improvement (CGI-I) Scale.65,66 Again, these 
studies did not include sufficient numbers of subjects aged Neuropsychiatric Disease and Treatment 2010:6 53
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65 and over to determine whether they respond differently 
from younger patients.
Major depressive disorder
The use of aripiprazole for MDD in older patients has 
been looked at only in a limited fashion. One open trial of 
aripiprazole augmentation in 20 older adults with MDD 
that had not remitted after 6 weeks of treatment with a 
selective serotonin reuptake inhibitor (SSRI) was associated 
with improvement in 50% of the patients.67 Another 
12-week, open-label pilot study of 24 patients diagnosed with 
MDD who responded partially (17-item Hamilton Rating 
Scale for Depression [HAM-D-17] score of 11 to 15) or not 
at all (HAM-D score 15) to a 16-week trial of escitalopram 
(up to 20 mg/day), followed by either duloxetine (up to 
120 mg/day) or venlafaxine (up to 225 mg/day) for 12 weeks. 
Subjects received 2.5 to 15 mg per day of adjunctive aripip-
razole (mean dose, 9.0 mg/day) for 12 weeks. The criterion 
for remission during treatment with aripiprazole was a 
HAM-D score 10 for 2 consecutive weeks. Of 24 subjects 
in the intent-to-treat study group, 19 completed 12 weeks 
of augmentation with aripiprazole, 12 of 24 (50%) met 
criteria for remission, and 2 of 24 discontinued due to side 
effects (sedation, akathisia). The mean (SD) HAM-D score 
decreased significantly by 6.4 (5.8) points (paired t test for 
means, P  0.01, df = 16). There were no relapses among 
the 12 subjects who participated in continuation treatment 
over a median period of 27.6 weeks.68 No known randomized 
controlled trials have looked at this phenomenon.
Aripiprazole: safety and tolerability
Second-generation antipsychotics (SGAs) are used to treat 
psychiatric conditions in elderly patients, including schizo-
phrenia, mood disorders, and dementia with agitation and 
delusions.25 Aripiprazole is a SGA with partial agonist 
activity at the D2, D3, and 5HT1A receptors and antagonist 
activity at the 5-HT2A receptors.39
Data from Phase ii and iii trials
In Phase II and III trials, aripiprazole exhibited a favorable 
safety and tolerability profile. It showed a low propensity 
to cause significant adverse effects, such as extrapyramidal 
side effects (EPS), weight gain, cardiovascular abnormali-
ties, hyperprolactinemia, hypercholesterolemia, or glucose 
dysregulation.49,69–70 In a meta-analysis assessing safety 
and tolerability data from the Phase II and Phase III trials, 
1539 patients receiving aripiprazole (n = 926), haloperidol 
(n = 200), or placebo (n = 413) were assessed. The reported 
incidence of common adverse effects with aripiprazole was 
comparable to that of placebo.71 The most common side 
effects reported with aripiprazole (10% incidence) were 
headache, insomnia, agitation, and anxiety. Other common 
side effects were dyspepsia, nausea and vomiting, lightnead-
edness, somnolence, constipation and akathisia. Discontinu-
ation due to adverse events occurred at an incidence rate of 
7% with aripiprazole compared to 8% with haloperidol and 
10% with placebo.71 The most frequent adverse events leading 
to discontinuation of aripiprazole included psychosis (3.6%), 
agitation (0.6%) and akathisia (0.6%). The incidence rate 
of EPS-related adverse events had no significant difference 
in between the placebo and aripiprazole treatment groups. 
Tardive dyskinesia was only reported by 2 of the aripipra-
zole-treated patients (0.2%).71 At endpoint, patients showed 
minimal mean increase in body weight from baseline (1 kg) 
on aripiprazole. In all, 8.1% of patients on aripiprazole 
experienced clinically significant weight gain (7% increase 
from baseline).71 Aripiprazole was associated with decreased 
in serum prolactin levels. There was no dose-response 
relationship between aripiprazole and changes in the QTc 
interval.71 The median increase in fasting total cholesterol 
from baseline observed with aripiprazole treatment was low 
and did not differ significantly from placebo. Only 5.5% 
of patients on aripiprazole had abnormally elevated fasting 
glucose levels and only 1.4% of the patients on aripiprazole 
had random levels of glucose above 200 mg/dL.71 There were 
no clinically important differences in the adverse event profile 
when stratified by age, gender or race in patients receiving 
aripiprazole.71
Metabolic profile
Metabolic syndrome is age dependent and more prevalent 
in older adults across cultures.72 Additional studies, have 
validated that aripiprazole has a favorable metabolic safety 
profile.40,73 One study of 31 patients with schizophrenia 
showed that there was a significant decrease in body weight, 
body mass index, and weight circumference after 3 months 
of treatment with aripiprazole. There was also a significant 
reduction in fasting glucose, fasting insulin, insulin resistance 
index and serum lipid levels.74 In addition, aripiprazole did 
not induce hyperprolactinemia at end point compared with 
baseline in a meta-analysis.60 In one trial, as compared to 
olanazpine, aripiprazole was associated with weight loss and 
lesser changes in total cholesterol.75
One retrospective chart review of 52 inpatient geri-
atric patients who received aripiprazole described side 
effects attributed to aripiprazole in the charts of 9 (17.3%) Neuropsychiatric Disease and Treatment 2010:6 54
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of the patients. Of these 9 patients, 7 had not received 
aripiprazole until the current hospitalization. Side effects 
were reported in a higher percentage of male than female 
patients (25% versus 15%); however, this did not reach 
statistical significance. The most commonly reported side 
effect was agitation/activation, which was documented in 
the charts of 4 patients (8%). Extrapyramidal symptoms 
were reported in 2 patients, and single cases of confusion, 
fatigue, and lightheadedness were also reported. The mean 
dose at which side effects were reported was 11.4 mg/day. 
Side effects were the reported reason for aripiprazole 
discontinuation in 12% or 6 of the patients.46
Patient-focused perspectives
Quality of life
Quality of life is important for all individuals, especially 
for people with schizophrenia on chronic medications. 
However, quality of life can be difficult to define and 
quantify as it relies on individual perception and self-
assessment. Definitions vary from “whatever the individual 
defines it to be” to those that emphasize fulfillment of 
personal goals.76 Quality of life in the geriatric population 
can be even harder to define as it may depend less on sexual 
dysfunction and more on functions of activities of daily 
living (eg, bathing, dressing, food preparation). Addition-
ally, studies on quality of life and patient adherence with 
aripiprazole (the STAR study) have excluded patients over 
65 years of age.77,78
Data on the impact of aripiprazole therapy on the quality 
of life of schizophrenic patients are scarce and character-
ized by conflicting results.79–81 The only double-blind study 
which compared changes in quality of life among patients 
on aripiprazole versus perphenazine treatment failed to 
demonstrate statistically significant differences between the 
groups.81 A Cochrane systemic review revealed no conclusive 
evidence of a clinically important improvement in quality 
of life as assessed by the Quality of Life Scale among 
154 patients receiving aripaprazole.82
Patients with schizophrenia often have cognitive deficits 
such as decreases in attention, executive function and motor 
skills which impede their quality of life.83 Typical antipsy-
chotics can contribute to such cognitive impairments through 
parkinsonism motor impairment or anticholinergic side 
effects. As an atypical antipsychotic, aripiprazole has shown 
a modest improvement in cognitive function, however such 
studies are few in number.84 On open label study revealed 
no improvement in neurocognitive function in patients on 
aripiprazole as compared to olanzapine.85
Patient satisfaction/acceptability
Patients over age 65 are at greater risk of metabolic side 
effects of antipsychotics because of their age and presence 
of comorbidities. Data on aripiprazole’s impact on metabolic 
measures specifically in the geriatric population are not 
available. Studies have suggested that aripiprazole has a 
lower risk for weight gain than other atypical antipsychotics.86 
A randomized trial of 173 overweight patients of all ages 
with schizophrenia or schizoaffective disorder compar-
ing aripiprazole with olanzapine found aripiprazole was 
associated with weight loss and less effect in total cholesterol 
at 16 weeks.75 Some findings suggest that older patients 
actually gain less weight than their younger counterparts 
from second-generation antipsychotics (SGA).87 Further-
more, patients with Alzheimer’s disease receiving SGAs 
may exhibit less weight gain than younger patients without 
dementia.88
Regular physical activity is associated with reduced 
incidence of metabolic syndrome from SGA. This is true 
for older adults too. Park et al demonstrated that yearlong 
exercise of at least 20 minutes daily at 3 or more metabolic 
equivalents was associated with reduced incidence of meta-
bolic risk factors.89 Reductions in body mass index were 
strongly associated with favorable changes in risk factors 
for metabolic syndrome.90 While all patients on SGA should 
be advised on exercise and diet to minimize the potential 
effects of the metabolic syndrome, older patients may have 
poor compliance due to physical or financial limitations. 
Difficulty obtaining healthier food choices because of cost 
or availability and inability to exercise due to physical func-
tional restrictions can make it harder for geriatric patients to 
comply with lifestyle changes.
Adherence
Nonadherence with prescribed medication regimens can 
result in increased morbidity, mortality, and resource 
utilization.91,92 Schizophrenic patients with poor adherence 
with antipsychotic medications have greater symptom 
levels,93 sustained functional impairment,94 poor community 
adjustment,95 higher risk of relapse,96 and more rehospital-
ization and emergency room use.97,98 A 2007 meta-analysis 
of hospitalization costs associated with antipsychotic 
nonadherence in the treatment of schizophrenia measured 
the impact of nonadherence in terms of direct healthcare 
costs or inpatient days. The study found poor adherence to 
antipsychotic medications was consistently associated with 
higher hospitalization costs with a higher risk of relapse and 
rehospitalization. However, the studies this article reviewed Neuropsychiatric Disease and Treatment 2010:6 55
Efficacy and safety of aripiprazole in the elderly Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
did not include the newer atypical antipsychotics including 
aripirazole, ziprasidone or paliperidone.99
Discussion
A variety of psychiatric conditions in the elderly can be treated 
with antipsychotic medications. Poor adherence to typical 
antipsychotics due to adverse reactions led to the newer atypi-
cal antipsychotics. However, the metabolic side effects of the 
second generation antipsychotics led to the development of 
a newer atypical antipsychotic, aripiprazole.
Older patients often require complex decision-making for 
medication management of psychiatric illness because they 
frequently have co-morbidity with medical conditions and are 
prescribed many other medications. They are at greater risk 
of metabolic and other side effects of antipsychotics because 
of their age and presence of comorbidities.
In particular, since the FDA black box warning that use 
of atypical antipsychotic medications in elderly patients with 
dementia nearly doubled the risk of death, clinicians, patients 
and caregivers are left with unclear choices for treating people 
with dementia with psychosis and/or severe agitation. Such 
behaviors are common and can cause considerable caregiver 
stress. The alternatives for treatment include no treatment, 
use of other psychotropic drugs, and psychotherapeutic and 
psychosocial interventions. No treatment may only be viable 
in mild cases or if symptoms are not disturbing to the patient 
or impairing function. There are limited studies on use of 
antidepressants, cholinesterase inhibitors and memantine for 
dementia related psychosis which generally were of limited 
utility (details are beyond the scope of this paper). There are 
limited randomized-control trials on the role of psychosocial 
and behavioral treatments for this population; however an 
individualized approach to such treatments may be appropri-
ate for some patients.100 Even though there is no psychotropic 
medication that is approved by the FDA for the treatment of 
psychosis in AD, a number of consensus statements prior to 
2004 recommend the use of atypical antipsychotic agents as 
a first-line pharmacologic approach to treatment.25 Careful 
discussion of risks, benefits and alternative treatments should 
be conducted by clinicians with patients’ caregivers when 
using antipsychotic medications for patients with demen-
tia-related psychosis. Higher symptom burden will likely 
contribute to greater acceptance of using antipsychotic in 
hopes of improving quality of life.
In addition to its use in dementia, aripiprazole may be 
effective for the treatment of a variety of psychiatric condi-
tions in the elderly including psychosis due to schizophrenia, 
bipolar disoder, depression, and PD. Although the data on 
aripiprazole’s efficacy in the treatment of psychosis in the 
geriatric population are very limited, it may have an important 
role to play in those conditions. As discussed in detail above, 
aripiprazole has a favorable metabolic profile compared 
to other second-generation agents in terms of glycemic 
control, lipid profiles, prolactin levels and weight gain. When 
appropriate, clinicians should weigh the limited evidence of 
efficacy in the geriatric population with the potential benefits 
of less metabolic complications as its metabolic risk profile 
makes aripiprazole an attractive agent in this population. 
Additional studies on efficacy of aripiprazole use in the 
elderly population are needed, although early studies show 
some promise.
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